Higher levels of genetic mutations linked to improved outcomes in lung cancer patients

According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in patients using pembrolizumab (Keytruda) to treat non-small cell lung cancer (NSCLC).

From http://besthealthnews.com/2019/09/higher-levels-of-genetic-mutations-linked-to-improved-outcomes-in-lung-cancer-patients/?utm_source=rss&utm_medium=rss&utm_campaign=higher-levels-of-genetic-mutations-linked-to-improved-outcomes-in-lung-cancer-patients

from
https://healthnews010.wordpress.com/2019/09/28/higher-levels-of-genetic-mutations-linked-to-improved-outcomes-in-lung-cancer-patients/

From https://jamesjohnson10.blogspot.com/2019/09/higher-levels-of-genetic-mutations.html

from
https://jamesjohnson10.wordpress.com/2019/09/28/higher-levels-of-genetic-mutations-linked-to-improved-outcomes-in-lung-cancer-patients/